{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:21:40Z","timestamp":1776784900316,"version":"3.51.2"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors (ICIs) are drugs growingly employed in cancer immunotherapy which have significantly improved the prognosis of several tumours. ICIs act by restoring the \u201cexhausted\u201d immune system and increasing the number of T cells active against pathogens losing tolerogenic signalling, which has been linked to an increased risk of infectious events. We present the case of a 67-year-old man with locally advanced lung adenocarcinoma treated with the anti-PD-L1 durvalumab. Three months after immunotherapy started, an apparent radiological progression was found with elements suggesting a parenchymal superinfection associated with weight loss, asthenia, and sputum emission. A bronchoalveolar lavage resulted positive for\n                    <jats:italic>Mycobacterium chimaera<\/jats:italic>\n                    , and treatment with amikacin iv (for eight weeks) and daily azithromycin, ethambutol, and rifampicin was started. Thirteen months after treatment started, the patient is alive with a stable lung condition. The case highlights the risk of non-tuberculous mycobacteria lung disease (NTM-LD) in patients receiving ICIs treatment. We hypothesise that durvalumab induced an exaggerated immune response toward the mycobacteria, leading to immunopathology and overt clinical manifestations. Clinicians should be aware of this possibility in patients receiving ICIs developing new signs\/symptoms related to the respiratory tract, especially in countries with a high prevalence of NTM-LD.\n                  <\/jats:p>","DOI":"10.1186\/s12879-023-08537-w","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T05:01:59Z","timestamp":1693803719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?"],"prefix":"10.1186","volume":"23","author":[{"given":"Cecilia","family":"Azzar\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gramegna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Ori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"8537_CR1","doi-asserted-by":"crossref","unstructured":"Amelio P, Portevin D, Hella J et al. HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses. Silvestri G, editor. J Virol. 2019; 93(5).","DOI":"10.1128\/JVI.01728-18"},{"issue":"6","key":"8537_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol Nature Publishing Group. 2011;12(6):492\u20139.","journal-title":"Nat Immunol Nature Publishing Group"},{"issue":"3","key":"8537_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","volume":"77","author":"T Morelli","year":"2022","unstructured":"Morelli T, Fujita K, Redelman-Sidi G, Elkington PT. Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax. 2022;77(3):304\u201311.","journal-title":"Thorax"},{"key":"8537_CR4","doi-asserted-by":"crossref","unstructured":"Kauffman KD, Sakai S, Lora NE et al. PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques. Sci Immunol. 2021; 6(55).","DOI":"10.1126\/sciimmunol.abf3861"},{"issue":"June","key":"8537_CR5","first-page":"1","volume":"13","author":"A Gramegna","year":"2022","unstructured":"Gramegna A, Lombardi A, Lor\u00e8 NI, et al. Innate and adaptive lymphocytes in non-tuberculous mycobacteria lung disease: a review. Front Immunol. 2022;13(June):1\u20139.","journal-title":"Front Immunol"},{"key":"8537_CR6","doi-asserted-by":"crossref","unstructured":"Lombardi A, Gramegna A, Ori M, Azzar\u00e0 C, Blasi F, Gori A. Non-tuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review. ERJ Open Res. 2022;:00364\u20132022.","DOI":"10.1183\/23120541.00364-2022"},{"issue":"3","key":"8537_CR7","doi-asserted-by":"publisher","first-page":"467e9","DOI":"10.1016\/j.cmi.2020.04.020","volume":"27","author":"SW Pan","year":"2021","unstructured":"Pan SW, Shu CC, Feng JY, et al. Impact of different subspecies on disease progression in initially untreated patients with Mycobacterium avium complex lung disease. Clin Microbiol Infect. 2021;27(3):467e9\u201314.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"8537_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1164\/rccm.201501-0067OC","volume":"191","author":"DP Boyle","year":"2015","unstructured":"Boyle DP, Zembower TR, Reddy S, Qi C. Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am J Respir Crit Care Med. 2015;191(11):1310\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"8537_CR9","doi-asserted-by":"publisher","first-page":"ofaa067","DOI":"10.1093\/ofid\/ofaa067","volume":"7","author":"K Fujita","year":"2020","unstructured":"Fujita K, Yamamoto Y, Kanai O, Okamura M, Nakatani K, Mio T. Development of Mycobacterium avium Complex Lung Disease in patients with Lung Cancer on Immune Checkpoint inhibitors. Open forum Infect Dis. 2020;7(3):ofaa067.","journal-title":"Open forum Infect Dis"},{"issue":"4","key":"8537_CR10","doi-asserted-by":"publisher","first-page":"e000866","DOI":"10.1136\/esmoopen-2020-000866","volume":"5","author":"K Anand","year":"2020","unstructured":"Anand K, Sahu G, Burns E, et al. Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open Elsevier Masson SAS. 2020;5(4):e000866.","journal-title":"ESMO Open Elsevier Masson SAS"},{"issue":"4","key":"8537_CR11","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1093\/cid\/ciaa241","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, et al. Treatment of non-tuberculous mycobacterial pulmonary disease: an official ats\/ers\/escmid\/idsa clinical practice guideline. Clin Infect Dis. 2020;71(4):E1\u2013E36.","journal-title":"Clin Infect Dis"},{"key":"8537_CR12","doi-asserted-by":"publisher","unstructured":"Prevots D, Rebecca, Theodore K, Marras. \u201cEpidemiology of human pulmonary infection with non-tuberculous mycobacteria: a review.\u201d Clin Chest Med vol. 36,1 (2015): 13\u201334. doi:https:\/\/doi.org\/10.1016\/j.ccm.2014.10.002.","DOI":"10.1016\/j.ccm.2014.10.002"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08537-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08537-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08537-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T09:06:34Z","timestamp":1700384794000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08537-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8537"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08537-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2693545\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The patient has provided informed consent to the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AL reports personal fees from Gilead Sciences Inc. and Isnmed Italy. AGr reports personal fees from Grifols, Chiesi, GSK, Vertex and Insmed Italy. MO reports personal fees from Grifols. FB reports grants and personal fees from AstraZeneca,  grants and personal fees from Chiesi, personal fees from Grifols, grants and personal fees from GSK, personal fees from Guidotti, personal fees from Insmed, grants and personal fees from Menarini, personal fees from Novartis, personal fee from OM pharma, personal fees from Pfizer personal fees, personal fees from Janssen, personal fees from Vertex, personal fees from Viatris, personal fees from Zambon, in the last three years outside the submitted work. All the other authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"573"}}